|
Patent landscape, scope, and claims summary: |
United States Patent 7,939,070 Claims and US Patent Landscape: What’s Covered, Who Owns It, and Where Invalidation/Design-Around Risk Sits
No complete claim text was provided for U.S. Patent 7,939,070, so a claim-by-claim analysis of scope, novelty, and enforceability cannot be produced without omitting material claim elements.
What does US Patent 7,939,070 claim scope cover, and what are the key claim elements?
Answer: Not determinable from the provided prompt because the claim set was not included.
What claim language typically drives infringement and validity for mechanical/pharma patents like 7,939,070
- Independent claim limitations usually control infringement scope (device/system composition, structural constraints, process steps, or functional results tied to specific means).
- Dependent claims narrow scope via add-on structural, compositional, or process features.
- Functional limitations can be high-risk if construed broadly without clear structural/algorithmic support.
Claim-construction pressure points that drive outcomes
- “Comprising” vs “consisting of” transitions: broad open-ended scope can increase infringement surface but also raise indefiniteness risk depending on prosecution history.
- “Configured to” / “effective amount” style functional language: construction hinges on specification support.
- Parameter ranges: validity often turns on anticipation/obviousness based on overlap with prior-art disclosures.
How strong is the patent estate around US 7,939,070 for method, formulation, and device/process variations?
Answer: Not determinable from the provided prompt.
How to map the patent landscape around a single US patent
- Identify:
- The earliest priority application(s)
- All family members (US continuations/divisionals and foreign equivalents)
- Citation network (forward and backward citations)
- Claim set changes over prosecution (amendment history, restriction requirements)
- Compare:
- Claim scope vs. later patents by competitors in the same technical space
- Overlap with known commercial embodiments and manufacturing process steps
Landscape outcomes that matter for licensing or design-around
- If the family is dominated by continuation claims with similar structure, enforceability can be strong but design-around may be narrow.
- If independent claims are broad but supported weakly in the specification, validity challenges on enablement/indefiniteness rise.
- If key claim features are “result-based” without structural anchors, courts often narrow scope.
When does US Patent 7,939,070 expire in the US, and does any patent term adjustment or extension apply?
Answer: Not determinable from the provided prompt.
US patent term basics that govern expiry
- For most utility patents: 20 years from earliest effective non-provisional filing date, subject to:
- Patent Term Adjustment (PTA)
- Patent Term Extension (PTE) for certain FDA-regulated products (if applicable)
How expiry timelines affect Paragraph IV or Section viii use cases
- Expiry timing drives:
- First generic/biosimilar launch window
- Settlement timing for branded entrants
- Strategic enforcement posture
What patents protect the same subject matter as US 7,939,070 (continuations, divisionals, and related families)?
Answer: Not determinable from the provided prompt.
Typical “same invention” cluster for a US patent
- Continuations: same specification, different claim sets
- Divisionals: carve-outs of restricted subject matter
- Related families: different claim strategies (process vs composition; kit vs use)
Why this matters in litigation
- If related patents cover adjacent embodiments, a license or settlement often bundles them.
- A narrow 7,939,070 claim can still be strategically valuable if sister patents provide broader coverage.
Who are the owners and assignees of US Patent 7,939,070, and how does ownership affect licensing and enforcement?
Answer: Not determinable from the provided prompt.
Ownership signals that change business strategy
- If assignee is a university/medical center: enforcement and licensing style can be different than pharma incumbents.
- If assignment history shows multiple transfers: chain-of-title diligence becomes mandatory for litigation readiness.
What is the litigation and enforcement history for US Patent 7,939,070 (including settlements and injunction outcomes)?
Answer: Not determinable from the provided prompt.
What to look for in enforcement history
- Case filings involving:
- Same patent-in-suit
- Same parties
- Same alleged products/processes
- Post-grant events:
- IPR/PGR petitions targeting independent claim limitations
- Outcomes (institution, final written decisions, claim amendments)
Why outcomes drive current value
- If independent claims were narrowed or invalidated, the enforceable core may be much smaller than the published claims suggest.
Are there invalidity risks for US 7,939,070 based on prior art, obviousness, or written description/enablement?
Answer: Not determinable from the provided prompt.
Common invalidity grounds for claim scope
- Anticipation (35 USC 102): single reference discloses all limitations
- Obviousness (35 USC 103): combination of references plus motivation
- Written description/enablement (35 USC 112): specification does not support the full breadth
- Indefiniteness (35 USC 112(b)): claim boundaries are not clear
What design-around strategies could avoid infringement of US 7,939,070 while staying functionally similar?
Answer: Not determinable from the provided prompt.
Typical design-around vectors
- Swap structural elements with equivalents that fall outside the claimed structural definition
- Use alternative process steps or order while achieving the same end result
- Adjust parameter ranges outside the claimed critical ranges
- Use different compositions or materials not encompassed by “includes” language
How does US Patent 7,939,070 compare with competing patents in the same technological field?
Answer: Not determinable from the provided prompt.
Comparison methodology
- Build a two-layer claim matrix:
- Layer 1: independent claim features
- Layer 2: dependent claims that narrow the invention
- Compare those features to:
- Competitors’ latest granted patents
- Published applications
- Common industry technical standards
What would be the US regulatory pathway impact if US 7,939,070 relates to a drug, biologic, or device?
Answer: Not determinable from the provided prompt.
If it is pharma-related: what to check
- FDA Orange Book for any listed patents tied to an approved drug
- 505(b)(2) and ANDA referencing patterns
- 351(k) biosimilar pathways if biologic-related
Key Takeaways
- A comprehensive, critical analysis of U.S. Patent 7,939,070 cannot be produced because the prompt does not include the claim text.
- Without the claim set, scope, infringement surface, validity vulnerabilities, landscape mapping, and expiration/estrategy questions cannot be answered without omission.
FAQs
- How do I extract the enforceable core of a US patent without the claim text?
- What claim features usually decide validity in IPR petitions for US patents like 7,939,070?
- How do continuation filings around a single US patent typically change licensing value?
- What evidence most often drives claim construction outcomes in district court versus PTAB?
- How do Orange Book listings change generic launch risk assessment when a patent is in the same family as 7,939,070?
References
No sources were cited because the required patent claim content and bibliographic/patent metadata for U.S. Patent 7,939,070 were not provided in the prompt.
More… ↓
⤷ Start Trial
|
